HMG-CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women

C.J.M. Doggen; R.N. Lemaitre; N.L. Smith; S.R. Heckbert; B.M. Psaty

doi:10.1111/j.1538-7836.2004.00696.x

HMG-CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women

C.J.M. Doggen (Corresponding Author), R.N. Lemaitre, N.L. Smith, S.R. Heckbert, B.M. Psaty

Research output: Contribution to journal › Article › Academic › peer-review

81 Citations (Scopus)

11 Downloads (Pure)

Abstract

In addition to lowering blood lipid levels, statins (HMG CoA reductase inhibitors) inhibit platelet aggregation and maintain a favorable balance between prothrombotic and fibrinolytic mechanisms [1]. Perhaps these effects may account for the association of statins with a reduced risk of venous thrombosis [2,3]. Because different statins have different properties [4], the possibility that the risk of venous thrombosis varied by specific statin was also investigated.

Original language	English
Pages (from-to)	700-701
Journal	Journal of thrombosis and haemostasis
Volume	2
Issue number	5
DOIs	https://doi.org/10.1111/j.1538-7836.2004.00696.x
Publication status	Published - 2004
Externally published	Yes

Access to Document

10.1111/j.1538-7836.2004.00696.x

Fingerprint Dive into the research topics of 'HMG-CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women'. Together they form a unique fingerprint.

Cite this

@article{43cecb89d19f44c4b7ab9b34d7210594,

title = "HMG-CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women",

abstract = "In addition to lowering blood lipid levels, statins (HMG CoA reductase inhibitors) inhibit platelet aggregation and maintain a favorable balance between prothrombotic and fibrinolytic mechanisms [1]. Perhaps these effects may account for the association of statins with a reduced risk of venous thrombosis [2,3]. Because different statins have different properties [4], the possibility that the risk of venous thrombosis varied by specific statin was also investigated.",

author = "C.J.M. Doggen and R.N. Lemaitre and N.L. Smith and S.R. Heckbert and B.M. Psaty",

year = "2004",

doi = "10.1111/j.1538-7836.2004.00696.x",

language = "English",

volume = "2",

pages = "700--701",

journal = "Journal of thrombosis and haemostasis",

issn = "1538-7933",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - HMG-CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women

AU - Doggen, C.J.M.

AU - Lemaitre, R.N.

AU - Smith, N.L.

AU - Heckbert, S.R.

AU - Psaty, B.M.

PY - 2004

Y1 - 2004

N2 - In addition to lowering blood lipid levels, statins (HMG CoA reductase inhibitors) inhibit platelet aggregation and maintain a favorable balance between prothrombotic and fibrinolytic mechanisms [1]. Perhaps these effects may account for the association of statins with a reduced risk of venous thrombosis [2,3]. Because different statins have different properties [4], the possibility that the risk of venous thrombosis varied by specific statin was also investigated.

AB - In addition to lowering blood lipid levels, statins (HMG CoA reductase inhibitors) inhibit platelet aggregation and maintain a favorable balance between prothrombotic and fibrinolytic mechanisms [1]. Perhaps these effects may account for the association of statins with a reduced risk of venous thrombosis [2,3]. Because different statins have different properties [4], the possibility that the risk of venous thrombosis varied by specific statin was also investigated.

U2 - 10.1111/j.1538-7836.2004.00696.x

DO - 10.1111/j.1538-7836.2004.00696.x

M3 - Article

VL - 2

SP - 700

EP - 701

JO - Journal of thrombosis and haemostasis

JF - Journal of thrombosis and haemostasis

SN - 1538-7933

IS - 5

ER -